Ultrastable mucoadhesive gold nanoparticles for corneal drug delivery
Increasing the corneal residence time of drugs is a current challenge in ophthalmology. Drug vectors with such properties can increase the efficiency of drugs, thereby reducing the frequency of administration, the duration of treatment, and the risk of post-surgical infection that may lead to sight loss.
The team of Prof Boisselier has developed a new ocular drug nanotechnology-based vector, in the form of ultrastable mucoadhesive gold nanoparticles onto which drugs can be encapsulated, to provide an efficient drug-vector formulation to delivering anti-inflammatory drugs, such as those prescribed after cataract surgery, to a mucoid surface such as the cornea.
Boisselier É, M Ouellette, V Pernet, and M Omar (2018). Ultrastable gold nanoparticles for drug delivery applications and synthesis thereof. Patent pending. Assignee: Université Laval
Masse F, M Ouellette, G Lamoureux, and É Boisselier (2019). Gold nanoparticles in ophthalmology. Med Res Rev 39: 302-327.
Masse F, P Desjardins, M Ouellette, C Couture, MM Omar, V Pernet, S Guérin and É Boisselier (2019). Synthesis of ultrastable gold nanoparticles as a new drug delivery system. Molecules 24: E2929.
Ouellette M, F Masse, M Lefebvre-Demers, Q Maestracci, P Grenier, R Millar, N Bertrand, M Prieto, and É Boisselier (2018). Insights into gold nanoparticles as a mucoadhesive system. Sci Rep 8: 14357.
Ultrastable mucoadhesive gold nanoparticules can efficiently deliver drugs to the cornea and significantly increase their residence time.
SOVAR and Université Laval seek a partner for co-development, licensing, or commercialization of this technology.
The laboratory of Prof Boisselier can synthesize, functionalize, and characterize ultrastable gold nanoparticles, as well as encapsultating drugs for in vitro and in vivo studies.